134 related articles for article (PubMed ID: 29193025)
1. "Mouse-MRD" in central nervous system acute lymphoblastic leukaemia: assessing bone marrow minimal residual disease using a xenograft model - from bedside to the bench and back again.
Alten J; Claviez A; Vieth S; Cario G; Schewe DM
Br J Haematol; 2018 Nov; 183(4):686-688. PubMed ID: 29193025
[No Abstract] [Full Text] [Related]
2. Central nervous system involvement in acute lymphoblastic leukemia is mediated by vascular endothelial growth factor.
Münch V; Trentin L; Herzig J; Demir S; Seyfried F; Kraus JM; Kestler HA; Köhler R; Barth TFE; Te Kronnie G; Debatin KM; Meyer LH
Blood; 2017 Aug; 130(5):643-654. PubMed ID: 28550041
[TBL] [Abstract][Full Text] [Related]
3. Molecular detection of acute lymphoblastic leukaemia in boys with testicular relapse.
Lal A; Kwan E; al Mahr M; Zhou L; Ferrara D; Tobias V; O'Gorman Hughes D; Haber M; Norris MD; Marshall GM
Mol Pathol; 1998 Oct; 51(5):277-81. PubMed ID: 10193523
[TBL] [Abstract][Full Text] [Related]
4. Characteristics and Therapeutic Targeting of Minimal Residual Disease in Childhood Acute Lymphoblastic Leukemia.
Jeremias I; Schewe DM
Adv Exp Med Biol; 2018; 1100():127-139. PubMed ID: 30411264
[TBL] [Abstract][Full Text] [Related]
5. The role of ZAP70 kinase in acute lymphoblastic leukemia infiltration into the central nervous system.
Alsadeq A; Fedders H; Vokuhl C; Belau NM; Zimmermann M; Wirbelauer T; Spielberg S; Vossen-Gajcy M; Cario G; Schrappe M; Schewe DM
Haematologica; 2017 Feb; 102(2):346-355. PubMed ID: 27686375
[TBL] [Abstract][Full Text] [Related]
6. Practical application of minimal residual disease assessment in childhood acute lymphoblastic leukaemia annotation.
Goulden N; Oakhill A; Steward C
Br J Haematol; 2001 Feb; 112(2):275-81. PubMed ID: 11167819
[No Abstract] [Full Text] [Related]
7. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia after first relapse.
Coustan-Smith E; Gajjar A; Hijiya N; Razzouk BI; Ribeiro RC; Rivera GK; Rubnitz JE; Sandlund JT; Andreansky M; Hancock ML; Pui CH; Campana D
Leukemia; 2004 Mar; 18(3):499-504. PubMed ID: 14981525
[TBL] [Abstract][Full Text] [Related]
8. Minimal residual disease in children with acute lymphoblastic leukaemia.
Catovsky D; Farahat N; Matutes E; Powles RL; Pinkerton CR
Lancet; 1998 Apr; 351(9111):1287. PubMed ID: 9643774
[No Abstract] [Full Text] [Related]
9. Correlation of bone marrow minimal residual disease and apparent isolated extramedullary relapse in childhood acute lymphoblastic leukaemia.
O'Reilly J; Meyer B; Baker D; Herrmann R; Cannell P; Davies J
Leukemia; 1995 Apr; 9(4):624-7. PubMed ID: 7723395
[TBL] [Abstract][Full Text] [Related]
10. Minimal residual disease detection after allogeneic stem cell transplantation is correlated to relapse in patients with acute lymphoblastic leukaemia.
Uzunel M; Jaksch M; Mattsson J; Ringdén O
Br J Haematol; 2003 Sep; 122(5):788-94. PubMed ID: 12930390
[TBL] [Abstract][Full Text] [Related]
11. Minimal residual disease before and after transplantation for childhood acute lymphoblastic leukaemia: is there any room for intervention?
Balduzzi A; Di Maio L; Silvestri D; Songia S; Bonanomi S; Rovelli A; Conter V; Biondi A; Cazzaniga G; Valsecchi MG
Br J Haematol; 2014 Feb; 164(3):396-408. PubMed ID: 24422724
[TBL] [Abstract][Full Text] [Related]
12. Minimal residual disease after induction is the strongest predictor of prognosis in intermediate risk relapsed acute lymphoblastic leukaemia - long-term results of trial ALL-REZ BFM P95/96.
Eckert C; von Stackelberg A; Seeger K; Groeneveld TW; Peters C; Klingebiel T; Borkhardt A; Schrappe M; Escherich G; Henze G
Eur J Cancer; 2013 Apr; 49(6):1346-55. PubMed ID: 23265714
[TBL] [Abstract][Full Text] [Related]
13. Bone marrow aspiration technique may have an impact on therapy stratification in children with acute lymphoblastic leukaemia.
Helgestad J; Rosthøj S; Johansen P; Varming K; Østergaard E
Pediatr Blood Cancer; 2011 Aug; 57(2):224-6. PubMed ID: 21360660
[TBL] [Abstract][Full Text] [Related]
14. Persistent MRD before and after allogeneic BMT predicts relapse in children with acute lymphoblastic leukaemia.
Sutton R; Shaw PJ; Venn NC; Law T; Dissanayake A; Kilo T; Haber M; Norris MD; Fraser C; Alvaro F; Revesz T; Trahair TN; Dalla-Pozza L; Marshall GM; O'Brien TA
Br J Haematol; 2015 Feb; 168(3):395-404. PubMed ID: 25312094
[TBL] [Abstract][Full Text] [Related]
15. Regulation of the bone marrow microenvironment by G-CSF: Effects of G-CSF on acute lymphoblastic leukaemia.
Basnett J; Xie V; Cisterne A; Bradstock K; Bendall L
PLoS One; 2017; 12(11):e0188042. PubMed ID: 29145456
[TBL] [Abstract][Full Text] [Related]
16. Comparison of chimerism and minimal residual disease monitoring for relapse prediction after allogeneic stem cell transplantation for adult acute lymphoblastic leukemia.
Terwey TH; Hemmati PG; Nagy M; Pfeifer H; Gökbuget N; Brüggemann M; Le Duc TM; le Coutre P; Dörken B; Arnold R
Biol Blood Marrow Transplant; 2014 Oct; 20(10):1522-9. PubMed ID: 24907626
[TBL] [Abstract][Full Text] [Related]
17. Pre- and post-transplant minimal residual disease predicts relapse occurrence in children with acute lymphoblastic leukaemia.
Lovisa F; Zecca M; Rossi B; Campeggio M; Magrin E; Giarin E; Buldini B; Songia S; Cazzaniga G; Mina T; Acquafredda G; Quarello P; Locatelli F; Fagioli F; Basso G
Br J Haematol; 2018 Mar; 180(5):680-693. PubMed ID: 29359790
[TBL] [Abstract][Full Text] [Related]
18. Adhesion to osteopontin in the bone marrow niche regulates lymphoblastic leukemia cell dormancy.
Boyerinas B; Zafrir M; Yesilkanal AE; Price TT; Hyjek EM; Sipkins DA
Blood; 2013 Jun; 121(24):4821-31. PubMed ID: 23589674
[TBL] [Abstract][Full Text] [Related]
19. Immunoglobulin gene rearrangement in detection of minimal residual disease in acute lymphoblastic leukaemia.
Nayyar A; Ahmed S
J Ayub Med Coll Abbottabad; 2013; 25(1-2):159-61. PubMed ID: 25098084
[TBL] [Abstract][Full Text] [Related]
20. Impact of minimal residual disease on outcomes after umbilical cord blood transplantation for adults with Philadelphia-positive acute lymphoblastic leukaemia: an analysis on behalf of Eurocord, Cord Blood Committee and the Acute Leukaemia working party of the European group for Blood and Marrow Transplantation.
Tucunduva L; Ruggeri A; Sanz G; Furst S; Cornelissen J; Linkesch W; Mannone L; Ribera JM; Veelken H; Yakoub-Agha I; González Valentín ME; Schots R; Arcese W; Montesinos P; Labopin M; Gluckman E; Mohty M; Rocha V
Br J Haematol; 2014 Sep; 166(5):749-57. PubMed ID: 24961645
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
